Document Detail


Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
MedLine Citation:
PMID:  19932926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Cyclosporine is a valuable option for the treatment of psoriasis. This report summarizes studies regarding the use of cyclosporine since the last guidelines were published in 1998. OBJECTIVE: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options. Our aim was to achieve a consensus on new updated guidelines for the use of cyclosporine in the treatment of psoriasis. METHODS: Reports in the literature were reviewed regarding cyclosporine therapy. LIMITATIONS: There are few evidence-based studies on the treatment of psoriasis with cyclosporine. RESULTS: A consensus was achieved on the use of cyclosporine in psoriasis including specific recommendations on dosing, monitoring, and use of cyclosporine in special situations. The consensus received approval from members of the National Psoriasis Foundation Medical Board. CONCLUSIONS: Cyclosporine is a safe and effective drug for the treatment of psoriasis. It has a particularly useful role in managing psoriatic crises, treating psoriasis unresponsive to other modalities, bridging to other therapies, and treating psoriasis within a rotational scheme of other medications. Appropriate patient selection and monitoring will significantly decrease the risks of side effects.
Authors:
David M Rosmarin; Mark Lebwohl; Boni E Elewski; Alice B Gottlieb;
Related Documents :
15723366 - Psychosocial treatments for adhd in teens and adults: a practice-friendly review.
7356436 - Intravenous histamine in otologic practice. side effects in 2,347 administrations.
7614666 - Rural campaign to diagnose and treat mucocutaneous leishmaniasis in bolivia.
9830356 - Dysfunctional uterine bleeding.
20481646 - Cardiovascular effects of medications for the treatment of attention-deficit hyperactiv...
997596 - A statistical analysis of reviewer agreement and bias in evaluating medical abstracts.
Publication Detail:
Type:  Consensus Development Conference; Journal Article; Practice Guideline; Review     Date:  2009-11-24
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  62     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-19     Completed Date:  2010-05-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  838-53     Citation Subset:  IM    
Copyright Information:
Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Affiliation:
Department of Dermatology at Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Animals
Child
Cyclosporine / adverse effects,  contraindications,  therapeutic use*
Drug Interactions
Female
HIV Infections / complications
Hepatitis C, Chronic / physiopathology
Humans
Hypertension / chemically induced
Kidney Diseases / chemically induced
Pregnancy
Psoriasis / drug therapy*
Chemical
Reg. No./Substance:
59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemical characterization of Phoma pomorum isolated from Danish maize.
Next Document:  Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disub...